The European dipeptidyl peptidase 4 (DPP-4) inhibitors market is projected to grow at a modest CAGR of 3.3% during the forecast period (2020-2026). The key aspect that drives the growth of the market includes the rising cases of type 2 diabetes among the people in the European region. The rising geriatric population which is more prone to diseases and their side effects, well developed and enhanced healthcare infrastructure, and the footprints of major key players are also some other factors that contribute to the growth of the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market. However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market over the forecast period.

Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type. Based on the drug type, the market is segmented as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others. Amongst these drug types of the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors, the Sitagliptin and Saxagliptin are projected to hold the most lucrative share in the market. Geographically, the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK is anticipated to grow considerably over the forecast period. 

Further, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, SatRx LLC, and Takeda Pharmaceutical Co. among others are some of the prominent players functioning in the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market. 

Research Methodology

The market study of the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

• Financial reports of companies involved in the market
• Whitepapers, research-papers, and news blogs
• Company websites and their product catalog

The report is intended for pharmaceutical companies, dipeptidyl peptidase 4 (DPP-4) inhibitors manufacturers, research institutes and universities, other related companies, and government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Europe Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Research and Analysis by Drug Type

The Report covers:

• Comprehensive research methodology of the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Europe Dipeptidyl peptidase 4 (DPP-4) inhibitors market.
• Insights about market determinants which are stimulating the Europe dipeptidyl peptidase 4 (DPP-4) inhibitors market.
• Detailed and extensive market segments with regional distribution of forecast revenues.
• Extensive profiles and recent developments of the market players.